Eiger BioPharmaceuticals, Inc. Stock Price, News & Analysis

Eiger BioPharmaceuticals (Nasdaq: EIGR) announced that the FDA has granted Breakthrough Therapy Designation for avexitide, aimed at treating congenital hyperinsulinism (HI), a serious pediatric condition. This designation accelerates drug development for conditions with unmet medical needs. Avexitide, a GLP-1 antagonist, showed promise in three Phase 2 studies with 39 patients, indicating potential improvements in treatment outcomes. The company also plans a Phase 3 study for post-bariatric hypoglycemia, as avexitide is not yet approved for any indication.

Eiger BioPharmaceuticals, based in Palo Alto, California, announced participation in two investor conferences on August 10, 2021. David Cory, President and CEO, will engage in a fireside chat at the BTIG Virtual Healthcare Conference at 1:00 PM ET, followed by a panel discussion on liver diseases at the Wedbush PacGrow Healthcare Virtual Conference at 2:20 PM ET. Eiger's lead programs target hepatitis delta virus with treatments in Phase 3 trials. The company's first FDA-approved product is Zokinvy, designed for treating Hutchinson-Gilford Progeria Syndrome.

Eiger BioPharmaceuticals (Nasdaq: EIGR) will hold a conference call on August 5, 2021, at 4:30 PM ET to discuss its second-quarter 2021 financial results and provide a business update. The call will be accessible via phone and through a webcast on Eiger's website. The company specializes in therapies for serious rare diseases, focusing on Hepatitis Delta Virus with its lead clinical programs including Lonafarnib and Peginterferon lambda, and holds a first FDA-approved product, Zokinvy, for Progeria. A Marketing Authorization Application is under review by the EMA for Zokinvy.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a biopharmaceutical company dedicated to rare diseases, will present a corporate update at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 1:00 PM EDT. David Cory, President and CEO, will lead the presentation. A live webcast will be available on Eiger's website, with a replay accessible one hour post-event. Eiger is focused on therapies for Hepatitis Delta Virus and has FDA approval for Zokinvy®, targeting Hutchinson-Gilford Progeria Syndrome.

Eiger BioPharmaceuticals announced that the first patients were dosed with Peginterferon Lambda in the Phase 3 TOGETHER study targeting COVID-19 outpatients. This randomized, placebo-controlled study aims to compare clinical outcomes in patients at high risk for complications. Peginterferon Lambda is a well-tolerated interferon designed to stimulate immune responses, potentially addressing ongoing SARS-CoV-2 variants. Eiger is optimistic about Lambda's role in treating COVID-19 and plans to release study results in the future.

Eiger BioPharmaceuticals (Nasdaq: EIGR) announced the grant of stock options to purchase 45,000 shares to a new employee, approved by its Compensation Committee. This grant, part of the 2021 Inducement Plan, has a ten-year term with an exercise price of $8.52, equal to the stock's closing price on June 30, 2021. The options vest over four years, with 25 percent vesting after one year, contingent on continued employment. This disclosure is made under Nasdaq Listing Rule 5635(c)(4).

Eiger BioPharmaceuticals (Nasdaq:EIGR) received the 2021 Rare Impact Award from NORD for its innovation in developing Zokinvy^® (lonafarnib), the first FDA-approved therapy for reducing the risk of death in Hutchinson-Gilford Progeria Syndrome and processing-deficient progeroid laminopathies. This recognition highlights Eiger's commitment to addressing the needs of the rare disease community, achieved through partnerships with The Progeria Research Foundation and Boston Children's Hospital. Zokinvy is currently under review by the European Medicines Agency.

Eiger BioPharmaceuticals (Nasdaq: EIGR) announced positive Phase 2 results of its drug Avexitide for treating congenital hyperinsulinism (HI) at the American Diabetes Association's 81st Scientific Session. The study involved 13 neonates and infants, showcasing a significant reduction in glucose infusion requirements (p=0.0087). At the highest dose, Avexitide eliminated glucose requirements in 50% of patients. The drug demonstrated good tolerability with no serious adverse events. Eiger aims to advance Avexitide for regulatory approval in 2022.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced that CEO David Cory will present a corporate update at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 PM EDT. A live webcast will be available on Eiger's website, with a replay accessible one hour after the event. Eiger specializes in targeted therapies for rare diseases, with key programs focusing on Hepatitis Delta Virus and its FDA-approved product, Zokinvy^®, for Hutchinson-Gilford Progeria Syndrome. The company will also conduct virtual one-on-one meetings with investors.